EGFR and dermatological toxicity: Several retrospective analyses of large randomized trial using anti‐EGFR ab plus standard chemotherapy for RAS wild‐type mCRC have reported that the appearance of severe skin toxicity reactions is associated with better survival outcomes.8, 12, 13 However, these observations might be confounded by differences in treatment exposure, because responding patients were likely to undergo a longer duration of treatment, leading to greater cumulative toxicity as well as the better prognosis.